Carlton Julie Garon, Marembo Joan, Manangazira Portia, Rupfutse Maxwell, Shearley Adelaide, Makwabarara Egnes, Hidle Anna, Loharikar Anagha
CDC Foundation, Atlanta, GA, United States of America.
Global Immunization Division, Centers for Disease Control and Prevention, Atlanta, GA, United States of America.
PLOS Glob Public Health. 2022 Apr 6;2(4):e0000101. doi: 10.1371/journal.pgph.0000101. eCollection 2022.
The World Health Organization (WHO) recommends the human papillomavirus (HPV) vaccine for girls aged 9-14 years for cervical cancer prevention and encourages vaccinating multiple cohorts in the first year to maximize impact. The HPV vaccine was introduced nationwide in Zimbabwe in 2018 through a 1-week school-based campaign to multiple cohorts (all girls 10-14 years old), followed by a single cohort (grade 5 girls in school and age 10 girls out-of-school) in 2019. During the 2019 campaign, the multiple cohort's second dose was concurrently delivered with the single cohort's first dose. We interviewed national-level key informants, reviewed written materials, and observed vaccination sessions to document HPV vaccine introduction in Zimbabwe and identify best practices and challenges. Key informants included focal persons from government health and education ministries, in-country immunization partners, and HPV Vaccine Strategic Advisory Group members. We conducted a desk review of policy/strategy documents, introduction plans, readiness reports, presentations, and implementation tools. Vaccination sessions were observed in three provinces during the 2019 campaign. Key informants (n = 8) identified high cervical cancer burden, political will, vaccine availability, donor financing, and a successful pilot program as factors driving the decision to introduce the HPV vaccine nationally. The school-based delivery strategy was well accepted, with strong collaboration between health and education sectors and high community demand for vaccine identified as key contributors to this success. Challenges with transitioning from a multiple age-based to single grade- and age-based target population as well as funding shortages for operational costs were reported. Zimbabwe's first multiple cohort, school-based HPV vaccination campaign was considered successful-primarily due to strong collaboration between health and education sectors and political commitment; however, challenges vaccinating overlapping cohorts in the 2019 campaign were observed. Integration with existing health and vaccination activities and continued resource mobilization will ensure sustainability of Zimbabwe's HPV vaccination program in the future.
世界卫生组织(WHO)建议为9至14岁的女孩接种人乳头瘤病毒(HPV)疫苗以预防宫颈癌,并鼓励在第一年为多个队列接种疫苗,以实现最大影响。2018年,HPV疫苗通过为期1周的以学校为基础的活动在津巴布韦全国范围内推广至多个队列(所有10至14岁的女孩),随后在2019年推广至单个队列(在校五年级女生和10岁校外女生)。在2019年的活动中,多个队列的第二剂疫苗与单个队列的第一剂疫苗同时接种。我们采访了国家级关键信息提供者,查阅了书面材料,并观察了疫苗接种环节,以记录HPV疫苗在津巴布韦的引入情况,并确定最佳做法和挑战。关键信息提供者包括政府卫生和教育部的协调人、国内免疫合作伙伴以及HPV疫苗战略咨询小组成员。我们对政策/战略文件、引入计划、准备情况报告、演示文稿和实施工具进行了案头审查。在2019年的活动期间,在三个省份观察了疫苗接种环节。关键信息提供者(n = 8)确定宫颈癌负担高、政治意愿、疫苗供应、捐助资金以及成功的试点项目是推动在全国引入HPV疫苗这一决定的因素。以学校为基础的接种策略广受认可,卫生和教育部门之间的强有力合作以及社区对疫苗的高需求被确定为这一成功的关键因素。报告了从基于多个年龄组向基于单个年级和年龄组的目标人群过渡的挑战以及运营成本的资金短缺问题。津巴布韦首次以学校为基础的多个队列HPV疫苗接种活动被认为是成功的——主要归功于卫生和教育部门之间的强有力合作以及政治承诺;然而,在2019年的活动中观察到了为重叠队列接种疫苗的挑战。与现有卫生和疫苗接种活动的整合以及持续的资源筹集将确保津巴布韦HPV疫苗接种计划在未来的可持续性。